SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 22, 2004
AMERICAN PHARMACEUTICAL PARTNERS, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 0-31781 | | 68-0389419 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | |
| 1101 Perimeter Drive, Suite 300; Schaumburg, IL | | 60173-5837 |
| (Address of principal executive offices) | | (Zip Code) |
(847) 969-2700
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:
| | |
Exhibit No.
| | Description
|
| 99.1 | | Press Release issued by American Pharmaceutical Partners, Inc. dated July 22, 2004. |
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
The following information is furnished pursuant to Item 12, Disclosure of Results of Operations and Financial Condition.
On July 22, 2004, American Pharmaceutical Partners, Inc. (the “Company”) announced via press release the Company’s preliminary results for the quarter ended June 30, 2004. A copy of the Company’s press release is attached hereto as Exhibit 99.1. This Form 8-K and the attached exhibit are being furnished, but not filed, under Item 12 of Form 8-K.
In addition to reporting financial results in accordance with generally accepted accounting principles (GAAP), American Pharmaceutical Partners, Inc. presents non-GAAP financial measures, including specifically, non-GAAP pro forma net income and non-GAAP pro forma net income per share. These non-GAAP measures exclude ABRAXANE™ related expenses and the benefit of the one-time tax credit related to ABRAXANE™. The Company’s management believes that this presentation facilitates evaluation by management, investors and analysts of its core injectable business. These measures should be considered as supplemental to, and not as a substitute for or superior to, financial measures calculated in accordance with GAAP. A reconciliation of GAAP net income and non-GAAP pro forma net income is presented in the press release.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
AMERICAN PHARMACEUTICAL PARTNERS, INC. |
| |
By: | | /s/ Nicole S. Williams
|
| | | Nicole S. Williams Chief Financial Officer Date: July 22, 2004 |
EXHIBIT INDEX
| | |
Exhibit No.
| | Description
|
| 99.1 | | Press Release issued by American Pharmaceutical Partners, Inc. dated July 22, 2004 |
